Dyne Therapeutics (DYN) Other Accumulated Expenses (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Other Accumulated Expenses data on file, last reported at $18.0 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 21.56% year-over-year to $18.0 million in Q1 2026; TTM through Mar 2026 was $18.0 million, a 21.56% increase from a year earlier, with the FY2025 full-year figure at $17.1 million, up 10.93% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $18.0 million, up from $17.1 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for DYN reached as high as $26.9 million in Q3 2025 and fell as low as $3.8 million in Q1 2024.
• Historically, Other Accumulated Expenses has averaged $13.1 million across 5 years, with a median of $12.1 million in 2023.
• Across the five-year window, Other Accumulated Expenses tumbled 54.42% in 2023 and surged 285.76% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $11.1 million in 2022, then climbed by 9.23% to $12.1 million in 2023, then gained by 27.06% to $15.4 million in 2024, then climbed by 10.93% to $17.1 million in 2025, then increased by 5.61% to $18.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $18.0 million in Q1 2026, $17.1 million in Q4 2025, and $26.9 million in Q3 2025.